Drug Type Chemical drugs |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization NaNotics LLCStartup |
Active Organization NaNotics LLCStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Ankylosing Spondylitis | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Depression | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Diabetes Mellitus, Type 2 | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Psoriasis | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Rheumatoid Arthritis | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Sepsis | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Stress Disorders, Post-Traumatic | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |
Well Aging | Preclinical | US | NaNotics LLCStartup | 06 Dec 2023 |